Proudly supported by Diabetes NSW & ACT and Diabetes Queensland.
Research Review have published a review of a recent speaker event on; Rethinking initial injectable therapy for people with type 2 diabetes: glucagon-like peptide-1 receptor agonists or basal insulin?
Associate Professor Samantha Hocking from the Royal Prince Alfred Hospital and the University of Sydney reviewed the recently updated ADA/EASD guidelines and provided some guidance.
Associate Mark Kennedy provided an overview of the place of GLP-1 RAs and insulin from the perspective of a general practitioner. Finally, Bernadette Heenan provided an overview of the use of these agents from the perspective of a Credentialed Diabetes Educator working with Indigenous people.
Click below to read the full review.
Speaker Series – Rethinking initial injectable therapy for type 2 diabetes
